Gubra Announces Collaboration With Amylyx Pharmaceuticals

Reuters
30 Dec 2024
Dec 30 (Reuters) - Gubra A/S ::
*ANNOUNCES NEW COLLABORATION WITH AMYLYX PHARMACEUTICALS
*COLLABORATION TO DEVELOP NOVEL LONG-ACTING GLP-1 RECEPTOR ANTAGONIST
*WILL RECEIVE UPFRONT AND RESEARCH PAYMENTS
*MAY RECEIVE OVER $50 MILLION IN SUCCESS-BASED DEVELOPMENT, COMMERCIALIZATION MILESTONES PLUS MID-SINGLE DIGIT ROYALTIES ON WORLDWIDE NET SALES

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 30-DEC-202412:30:01.46 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10